Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selatogrel autoinjector for suspected recurrent acute myocardial infarction after recent myocardial infarction
jRCT2031250252Recruiting
- Sponsor
- Viatris
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in myocardial infarction (MI) comparing Selatogrel 16 mg with Placebo (2 arms). Primary endpoints: Clinical status by 6-point ordinal scale and Type 3 or 5 treatment-emergent bleeding events by BARC definition. Started Jul 2025; status: recruiting.
02
Drugs
selatogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on jRCT2031250252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250252.